Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 121,559

Document Document Title
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/088957A1
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...  
WO/2021/088495A1
Provided are a crystal form I of a curcumin derivative (C66), a preparation method therefor and an application thereof, which relate to the field of the medical and chemical industry. The crystal form I contains characteristic peaks meas...  
WO/2021/088645A1
Disclosed are a new crystal form of Aprocitentan (referred to as "Compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of dual endotheli...  
WO/2021/089683A1
The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medi...  
WO/2021/089761A1
The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of suc...  
WO/2021/091846A1
The present disclosure relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of mast cell diseases and eosinophilic disorders.  
WO/2021/090061A1
Described herein are methods of for treating and/or preventing Major adverse cardiovascular events (MACE), by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compo...  
WO/2021/090926A1
This agent for preventing or treating arrhythmia is characterized by containing hydrogen.  
WO/2021/088672A1
A composition containing a legoamodipine besylate hydrate and a preparation method therefor, a preparation thereof, and a use thereof, especially a composition of (S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1, 4-dihydro-3,5...  
WO/2021/090945A1
The purpose of the present invention is to provide a cell culture for treating a peripheral arterial disease, a method for manufacturing the cell culture, a method for treating a peripheral arterial disease that uses the cell culture, an...  
WO/2021/089300A1
The present invention relates to compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3- isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and/or TT002), or a pharmaceutical composition comprising said TT00, TT001 and/or TT0...  
WO/2021/091356A1
The present invention relates to a pharmaceutical composition, a functional food composition, and a cosmetic composition which include methyl benzoate or a derivative thereof as an active ingredient, and are for preventing or treating st...  
WO/2021/089032A1
Disclosed are a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt...  
WO/2021/089776A1
The present invention relates to a compound of formula (I) for use in the treatment or prevention of a traumatic brain disorder.  
WO/2021/091593A1
The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for...  
WO/2021/085550A1
A fluorinated pyrimidine compound represented by general formula (1), (2), or (3). (In general formulas (1)-(3): R represents a C1-12 hydrocarbon group; X and Y each independently represent a hydrogen atom, a halogen atom, a C1-10 hydroc...  
WO/2021/083201A1
Provided in the present invention are a keratin BD-10, an encoding nucleic acid molecule thereof, an expression vector, a host cell, a preparation method for the keratin BD-10, and a pharmaceutical composition comprising the keratin BD-1...  
WO/2021/083206A1
Provided are a keratin BD-17, a nucleic acid molecule encoding the keratin BD-17, an expression vector containing the nucleic acid molecule, a host cell which contains the expression vector or in which the genome integrates the nucleic a...  
WO/2021/086271A1
A composition containing mulberry extract comprises of at least a mulberry extract, a sweetener, and an additive; wherein the mulberry extract is obtained from an extraction of leaves or fruits by a solvent, e.g. water or alcohol, or obt...  
WO/2021/085540A1
Provided are: a novel fluorine-containing pyrimidine compound with substituents at the 4-position, the 5-position, and the 6-position and a furan ring structure as a substituent at the 2-position; and a manufacturing method by which the ...  
WO/2021/083205A1
The present invention provides keratin BD-15, an encoding nucleic acid molecule thereof, an expression vector, a host cell, a preparation method for the keratin BD-15, and a pharmaceutical composition containing same. Further provided is...  
WO/2021/082882A1
Disclosed is a method for anchoring and modifying a nano-drug on the surface of a living cell. The method comprises: introducing an active reaction group to the surface of a living cell by means of a hydrophobic tail chain of a cell memb...  
WO/2021/083192A1
The present invention provides keratin BD-3, a nucleic acid molecule encoding same, an expression vector thereof, a host cell thereof, a preparation method therefor, and a pharmaceutical composition containing same. The keratin BD-3 can ...  
WO/2021/083200A1
Provided are a keratin BD-6, a nucleic acid molecule encoding the keratin BD-6, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrating the nucleic acid molecule, a pr...  
WO/2021/083203A1
Provided are a keratin BD-13, a coding nucleic acid molecule, expression vector, and host cell thereof and a preparation method therefor, and a pharmaceutical composition containing said keratin. Keratin BD-13 can be used to prepare anti...  
WO/2021/085295A1
The present invention addresses the problem of clarifying the immune response mechanism of IL-17-producing cells, said immune response mechanism inducing pathological conditions such as psoriasis, to thereby provide an immune response su...  
WO/2021/083202A1
Provided are keratin BD-11, an encoding nucleic acid molecule thereof, an expression vector, a host cell, a preparation method, and a pharmaceutical composition containing the keratin. The keratin BD-11 can be used for preparing drugs ha...  
WO/2021/083372A1
A solid composition containing angiotensin II, a preparation method and use method therefor and a use thereof. The composition comprises angiotensin II and an auxiliary additive, wherein the auxiliary additive comprises sulfobutyl beta c...  
WO/2021/084428A1
The present invention relates to compositions for oral use comprising at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Olea and at least an extract of a plant belonging to the genus Malus and t...  
WO/2021/086882A1
The present disclosure encompasses solid state forms of Arry-797, in embodiments crystalline polymorphs or salts or co-crystals of Arry-797, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2021/083204A1
Provided are keratin BD-14, a nucleic acid molecule encoding keratin BD-14, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a ...  
WO/2021/084229A1
A transdermal patch is provided, wherein the patch comprises a cross-linked poly(ethylene oxide) hydrogel loaded with naltrexone, or a pharmaceutically acceptable salt or solvate thereof, and an occlusive adhesive tape. The poly(ethylene...  
WO/2021/085592A1
The present invention provides a pharmaceutical composition for use in treatment of a disease caused by a mutation in collagen 3A1. This pharmaceutical composition is for treating a disease caused by a collagen 3A1 mutant in a subject ha...  
WO/2021/083190A1
Provided is a keratin BD-1, a nucleic acid molecule encoding the keratin BD-1, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrating the nucleic acid molecule, and a...  
WO/2021/084559A1
The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising spec...  
WO/2021/083209A1
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...  
WO/2021/083912A1
The present invention relates to novel uses of nitazoxanide, or analogues thereof.  
WO/2021/048195A3
This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevent...  
WO/2021/078132A1
The invention provides amides that inhibit apoptosis or induce autophagy through mTOR-mediated induction of autophagy, or inhibit a related disease such as cerebral ischemia/reperfusion or neurodegenerative diseases, including correspond...  
WO/2021/080396A1
The present invention relates to a composition for preventing or treating valvular heart disease, comprising an RSPO3 expression or activity inhibitor as an active ingredient. The RSPO3 expression or activity inhibitor can inhibit calcif...  
WO/2021/078288A1
Provided are activated insulin, a compound Momordica charantia peptide oral medicine for the treatment of diabetes, and a preparation method, comprising in parts by weight: 20-30 parts of Momordica charantia peptide, 4-6 parts of Panax q...  
WO/2021/077211A1
A pharmaceutical composition containing an effective amount of cannabidiol (CBD) for use in treating or preventing a heart condition, along with related methods and uses. The heart conditions include heart failure, acute myocarditis, tox...  
WO/2020/053865A9
The present invention relates to methods and compositions for engineering B cells to express transgenic B cell receptor (BCR) for antigen-induced antibody secretion, compositions, methods and uses thereof in immunotherapy.  
WO/2021/078295A1
Provided are a botanical medicine for treating hyperlipidemia and coronary heart disease and a method for preparation thereof, comprising the following raw materials in parts by weight: 20-25 parts of Ginkgo biloba extract, 10-12 parts o...  
WO/2021/079253A1
The present invention relates to a composition for oral use comprising at least an extract of red yeast rice, at least an extract of a plant belonging to the genus Allium and at least an extract of a plant belonging to the genus Malus an...  
WO/2021/081204A1
Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase ...  
WO/2021/078274A1
The present invention relates to a pyridazinone or pyridazine compound and a derivative and a pharmaceutical composition thereof. Specifically, the present invention provides a pyridazinone or pyridazine compound as shown in formula (I) ...  
WO/2021/081006A1
There are provided, in some embodiments, therapeutic compositions and methods for preventing, inhibiting, reducing, or treating cardiac ischemic reperfusion injury. The therapeutic composition can comprise a plurality of microRNA (miR) a...  
WO/2021/078835A1
The present invention relates to pharmaceutical compositions comprising 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu lfonyl)acetamide (selexipag, NS-304, ACT-293987) which are suitable for oral administratio...  

Matches 1 - 50 out of 121,559